2018
|
Sign up to set email alerts
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
Search citation statements
Order By: Relevance
Paper Sections
Select...
79
18
6
2
Citation Types
1
70
0
0
Year Published
Range
2019
20192026
2026Publication Types
Select...
76
21
2
1
Relationship
0
100
Authors
Journals
Cited by 100 publications
(71 citation statements)
References 23 publications
1
70
0
0
Order By: Relevance
Smart CitationsHow the paper below cites the one you are viewing
“…However, consistent with our findings, there are also examples of cancers in which PD‐L1 expression is associated with improved prognosis 32–34 . Consistent with our data, radiotherapy has previously been shown to increase PD‐L1 expression in soft tissue sarcoma and is known to reduce rates of local recurrence 35 . This phenomenon is not unique to sarcoma, with lung cancer (and others) also shown to increase PD‐L1 in response to radiotherapy 36 .…”
Section: Discussion
supporting
confidence: 90%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…However, consistent with our findings, there are also examples of cancers in which PD‐L1 expression is associated with improved prognosis 32–34 . Consistent with our data, radiotherapy has previously been shown to increase PD‐L1 expression in soft tissue sarcoma and is known to reduce rates of local recurrence 35 . This phenomenon is not unique to sarcoma, with lung cancer (and others) also shown to increase PD‐L1 in response to radiotherapy 36 .…”
Section: Discussion
supporting
confidence: 90%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…This would make comparative analyses reliable. Although radiotherapy has been shown to induce PD-L1 expression [33], our cases with documented post-radiotherapy (Table 1; n = 5) showed <10% PD-L1 expression. Finally, the size of the metastatic/recurrent cohort is limited and therefore, a larger number of paired samples is needed to further validate these findings.…”
Section: Fig 3 Matched Samples (A-d E-h and I-l Respectively) Pri
mentioning
confidence: 57%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…To identify the optimal modality for radiation/ICI combination therapy, further research regarding optimal dose/fractionation, field settings, combination timing and type of irradiation are required. By contrast, recent studies have demonstrated that radiotherapy also up-regulates PD-L1 in tumours (34,(37)(38)(39); therefore, combination therapy with ICIs is promising. Indeed, phase III clinical trials have revealed that combination therapy improves clinical outcomes in patients with locally advanced non-small cell lung cancer or metastatic castration-resistant prostate cancer (40)(41)(42)(43).…”
Section: Discussion
mentioning
confidence: 93%
Smart CitationsHow the paper below cites the one you are viewing
“…However, consistent with our findings, there are also examples of cancers in which PD‐L1 expression is associated with improved prognosis 32–34 . Consistent with our data, radiotherapy has previously been shown to increase PD‐L1 expression in soft tissue sarcoma and is known to reduce rates of local recurrence 35 . This phenomenon is not unique to sarcoma, with lung cancer (and others) also shown to increase PD‐L1 in response to radiotherapy 36 .…”
Section: Discussion
supporting
confidence: 90%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…This would make comparative analyses reliable. Although radiotherapy has been shown to induce PD-L1 expression [33], our cases with documented post-radiotherapy (Table 1; n = 5) showed <10% PD-L1 expression. Finally, the size of the metastatic/recurrent cohort is limited and therefore, a larger number of paired samples is needed to further validate these findings.…”
Section: Fig 3 Matched Samples (A-d E-h and I-l Respectively) Pri
mentioning
confidence: 57%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…To identify the optimal modality for radiation/ICI combination therapy, further research regarding optimal dose/fractionation, field settings, combination timing and type of irradiation are required. By contrast, recent studies have demonstrated that radiotherapy also up-regulates PD-L1 in tumours (34,(37)(38)(39); therefore, combination therapy with ICIs is promising. Indeed, phase III clinical trials have revealed that combination therapy improves clinical outcomes in patients with locally advanced non-small cell lung cancer or metastatic castration-resistant prostate cancer (40)(41)(42)(43).…”
Section: Discussion
mentioning
confidence: 93%
Smart CitationsHow the paper below cites the one you are viewing
“…However, consistent with our findings, there are also examples of cancers in which PD‐L1 expression is associated with improved prognosis 32–34 . Consistent with our data, radiotherapy has previously been shown to increase PD‐L1 expression in soft tissue sarcoma and is known to reduce rates of local recurrence 35 . This phenomenon is not unique to sarcoma, with lung cancer (and others) also shown to increase PD‐L1 in response to radiotherapy 36 .…”
Section: Discussion
supporting
confidence: 90%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…This would make comparative analyses reliable. Although radiotherapy has been shown to induce PD-L1 expression [33], our cases with documented post-radiotherapy (Table 1; n = 5) showed <10% PD-L1 expression. Finally, the size of the metastatic/recurrent cohort is limited and therefore, a larger number of paired samples is needed to further validate these findings.…”
Section: Fig 3 Matched Samples (A-d E-h and I-l Respectively) Pri
mentioning
confidence: 57%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…To identify the optimal modality for radiation/ICI combination therapy, further research regarding optimal dose/fractionation, field settings, combination timing and type of irradiation are required. By contrast, recent studies have demonstrated that radiotherapy also up-regulates PD-L1 in tumours (34,(37)(38)(39); therefore, combination therapy with ICIs is promising. Indeed, phase III clinical trials have revealed that combination therapy improves clinical outcomes in patients with locally advanced non-small cell lung cancer or metastatic castration-resistant prostate cancer (40)(41)(42)(43).…”
Section: Discussion
mentioning
confidence: 93%